Why did Charles River Laboratories (CRL) stock move recently?

On 9/2/2026, Charles River Laboratories moved +3.3% — CRL rose amid continued positive sentiment from its Q2 2026 earnings beat, raised full-year organic revenue and non-GAAP EPS guidance, and improving DSA demand trends reported in early August, with recent analyst commentary noting the stock holding near yearly highs. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Charles River Laboratories (CRL) overvalued or fairly valued?

MarketChacha shows Charles River Laboratories's valuation in context — a trailing P/E of about 157.7, a forward P/E of about 22.7, a price-to-book of about 4.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Charles River Laboratories's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (6.12×) from reported figures — education, not a rating.

What is Charles River Laboratories's revenue?

Charles River Laboratories reported revenue of $4.0B for FY2025, with net profit of $-144.3M, per official filings.

What is the share price of Charles River Laboratories (CRL)?

Charles River Laboratories last traded at $288.50 (-1.7% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Charles River Laboratories

CRL · NYSE · Healthcare · United States

Snapshot

TickerCRL

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees18,300

HeadquartersWilmington, United States

Websitewww.criver.com

Filings tracked19

About Charles River Laboratories

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Who owns it

Insiders0.5%
Institutions99.5%
Public & other0.0%

806 institutional holders

Ownership breakdown from public market data.

Top holders

FMR, LLC8.88%
Blackrock Inc.7.96%
Vanguard Capital Management LLC6.60%
Invesco Ltd.6.25%
Harris Associates L.P.4.69%
Vanguard Portfolio Management LLC4.63%
Allspring Global Investments Holdings, LLC3.99%
State Street Corporation3.91%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 15.1 points over the period — profitability is trending down.

Cash conversion6.12×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend11.5% → -3.6%

Margin has compressed by about 15.1 points over the period — profitability is trending down.

Return on equity-4.6%

Latest ROE of -4.6% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $952.7M · EPS 3.31

Est. earnings growth +38.7%

Next fiscal year

Rev $4.0B · EPS 12.69

Est. earnings growth +12.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$4.0B

Net margin

-3.6%

ROE

-4.6%

Revenue CAGR (2y)

-1.4%

EPS (FY2025)

-2.91

Net profit (FY2025)

$-144.3M

Ask MarketChacha about CRL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 2, 2026
CRL rose amid continued positive sentiment from its Q2 2026 earnings beat, raised full-year organic revenue and non-GAAP EPS guidance, and improving DSA demand trends reported in early August, with recent analyst commentary noting the stock holding near yearly highs.
source 1 ↗source 2 ↗source 3 ↗· confidence: medium
Jul 28, 2026
CRL shares rose on news of high-profile hedge fund investments including a new Maverick Capital stake via 13F filing, plus recent analyst price target upgrades and positive sentiment ahead of the Aug. 5 Q2 earnings release.
source 1 ↗source 2 ↗source 3 ↗· confidence: medium
Jul 23, 2026
CRL rose sharply and hit a 52-week high amid positive sentiment around 2026 guidance and drug development demand, despite recent mixed outlook commentary tied to Cambodian supply scrutiny.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$4.0B	$-144.3M	-2.91	-3.6%	-4.6%
FY2024	$4.0B	$22.2M	0.20	0.5%	0.6%
FY2023	$4.1B	$474.6M	9.22	11.5%	13.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.0B	$-1.5M	-0.03	-0.1%
2026Q1	$995.8M	$-14.8M	-0.30	-1.5%
2025Q3	$1.0B	$54.4M	1.10	5.4%
2025Q2	$1.0B	$52.3M	1.06	5.1%
2025Q1	$984.2M	$25.5M	0.50	2.6%
2024Q3	$1.0B	$69.7M	1.33	6.9%
2024Q2	$1.0B	$94.1M	1.74	9.2%
2024Q1	$1.0B	$73.0M	1.30	7.2%
2023Q3	$1.0B	$87.4M	1.69	8.5%
2023Q2	$1.0B	$103.1M	2.01	10.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC8/5/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/11/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Reg FD disclosure
SEC2/25/2026material
8-K — Results of operations, Exhibits
SEC2/18/2026material
10-K filing
SEC2/18/2026
8-K — Executive/director change, Exhibits
SEC2/18/2026material
8-K — Results of operations, Reg FD disclosure
SEC1/13/2026material
8-K — Executive/director change
SEC1/9/2026material

2025

8-K — Reg FD disclosure
SEC12/3/2025material
8-K — Other events
SEC11/17/2025material
8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K/A — Executive/director change
SEC9/19/2025
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/16/2025material
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.